In a report released today, Thomas Smith from SVB Securities maintained a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $9.00. The company's shares closed last Tuesday at $1.94, close to its 52-week low of $1.81. According to TipRanks.com, Smith is ranked 0 out of 5 stars with an average return of -30.5% and a 12.6% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Eledon Pharmaceuticals, and Prometheus Biosciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-connect-biopharma-holdings-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Connect Biopharma Charts.
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Connect Biopharma Charts.